Share Prices & Company Research

Stockbroking

Shire Plc

Current Price 0.00p Bid 0.00p Ask 0.00p Change 0.00%
Last Updated: 17/09/2024 07:08. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

Drugs group Shire Pharmaceuticals is best known for the attention deficit disorder treatments Adderall and Vyvanse. Founded in 1986 and became a listed company in 1996.

Financial Highlights Year Ended 31/12/2017

Revenue
£15,160.60m
Operating Profit/Loss
£2,455.20m
Dividend yield (%)
0.70
Total dividend for year
$n/a
Dividend cover
13.45
P/E Ratio
10.90
More Financials

Key Personnel

Ms Susan Kilsby
Chairman
Mr Flemming Ornskov
Chief Executive Officer
Mr Thomas Dittrich
Chief Financial Officer
Dr David Ginsburg
Non-Executive Director
Dr Steven Gillis
Non-Executive Director
Mr Albert P.L. Stroucken
Non-Executive Director
Mr Gail D. Fosler
Non-Executive Director
Mr Ian Clark
Non-Executive Director
Ms Sara Mathew
Non-Executive Director
Mr Olivier Bohuon
Senior Independent Director

Stock Details

EPIC
SHPL
ISIN
JE00B2QKY057
Shares in Issue
592.59m
Market cap
£0.00m

Price Summary

Mid Price
0.00p
Bid Price
0.00p
Ask Price
0.00p
Volume
0
Change Today
0.00p
% Change Today
0.00%
Open
0.00p
Previous Close
0.00p
Intraday High
0.00p
Intraday Low
0.00p
52 Week High
0.00p
52 Week Low
0.00p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

More Charts

News

Income Statement

Year End Date
31 Dec 2017
31 Dec 2016
 
$ (M)
$ (M)
Continuing Operations
Revenue
15,160.60
11,396.60
Operating Profit/Loss
2,455.20
962.90
Net Interest
-569.20
-451.20
Pre-Tax Profit
1,895.90
477.40
Profit After Tax from continuing operations
4,253.50
603.50
Discontinued Operations
Profit After Tax
18.00
-276.10
Profit/Loss for the Year
4,271.50
327.40
Attributable to:
Equity Holders of Parent Company
4,271.50
327.40
Minority Interests
n/a
n/a
Total Dividend Paid
$n/a
$n/a
Retained Profit/(Loss) for the Financial Year
n/a
n/a

Earnings per Share

Year End Date
31 Dec 2017
31 Dec 2016
Basic
469.00c
78.00c
Diluted
466.00c
77.00c
Adjusted
471.00c
43.00c
Dividend per Share
$n/a
$n/a

Assets

Year End Date
31 Dec 2017
31 Dec 2016
 
$ (M)
$ (M)
Non-Current Assets
Property, Plant & Equipment
6,635.40
6,469.60
Intangible Assets
52,877.80
52,585.70
Investment Properties
n/a
n/a
Investments
241.10
191.60
Other Financial Assets
n/a
n/a
Other Non-Current Assets
394.20
249.00
Current Assets
Inventories
3,291.50
3,562.30
Trade & Other Receivables
3,009.80
2,616.50
Cash at Bank & In Hand
472.40
528.80
Current Asset Investments
n/a
n/a
Other Current Assets
834.70
831.90
Other Assets
n/a
n/a
Total Assets
67,756.90
67,035.40

Liabilities

Year End Date
31 Dec 2017
31 Dec 2016
 
$ (M)
$ (M)
Current Liabilities
Borrowings
2,788.70
3,068.00
Other Current Liabilities
5,093.30
4,675.30
Total Current Liabilities
7,882.00
7,743.30
Non-Current Liabilities
Borrowings
16,752.40
19,899.80
Provisions
4,748.20
8,322.70
Other Non-Current Liabilities
2,197.90
2,121.60
Total Non-Current Liabilities
23,698.50
30,344.10
Other Liabilities
n/a
n/a
Total Liabilities
31,580.50
38,087.40

Net Assets

Year End Date
31 Dec 2017
31 Dec 2016
 
$ (M)
$ (M)
Net Assets
36,176.40
28,948.00

Capital & Reserves

Year End Date
31 Dec 2017
31 Dec 2016
 
$ (M)
$ (M)
Share Capital
81.60
81.30
Share Premium Account
n/a
n/a
Other Reserves
26,174.20
22,941.40
Retained Earnings
9,920.60
5,925.30
Shareholders Funds
36,176.40
28,948.00
Minority Interests/Other Equity
n/a
n/a
Total Equity
36,176.40
28,948.00

Dividend History

Dividend Metrics

Year End Date
31 Dec 2017
31 Dec 2016
Dividend growth
15.00%
15.02%
Dividend yield
0.70%
0.50%
Dividend cover
13.45
2.57


Cboe Global Markets® is a registered trade mark of Cboe Global Markets, Inc., a company incorporated in the United States of America with registered address at 400 South LaSalle Street, Chicago, IL 60605, USA. Cboe shall own any and all rights including without limitation Intellectual Property rights and any and all goodwill arising directly or indirectly out of the Recipient’s use of the “Cboe Global Markets®”, “Cboe®” and “Bats®”” trademarks. Neither Cboe nor its licensors accept any liability for any errors or omissions in the Cboe Europe Indices or underlying data. No further distribution of Cboe Europe data is permitted without Cboe’s express written consent.

The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.